Ascendis製藥 ASND 深 滬
已收盤 10-24 16:00:00 美东时间
202.00
+0.990
+0.49%
華盛通- 最 高208.81
- 今 開205.00
- 成交量 36.91万股
- 最 低 200.00
- 昨 收 201.01
- 總市值 122.32亿
- 52周最高 216.45
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 118.03
- 委 比 46.08%
- 總股本 6055.44万
- 歷史最高 216.45
- 量 比 0.72
- 振 幅 4.38%
- 歷史最低 11.92
- 每 手 1
- 風險率 26.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Raymond James Initiates Coverage On Ascendis Pharma with Strong Buy Rating, Announces Price Target of $271
Raymond James analyst Martin Auster initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Strong Buy rating and announces Price Target of $271.
10-17 23:32
Ascendis Pharma Grants Employee Warrants to Boost Engagement
Ascendis Pharma ( ($ASND) ) has shared an announcement. On October 14, 2025, As...
10-16 04:56
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
Ascendis Pharma Submits Marketing Authorisation Application To The European Medicines Agency For TransCon CNP As A Treatment For Children With Achondroplasia
COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon
10-09 04:03
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
Ascendis Pharma has submitted a Marketing Authorisation Application (MAA) to the EMA for TransCon CNP, a weekly-administered drug aimed at treating children with achondroplasia. The application is supported by data from clinical trials and open-label extensions, showing the drug is generally well-tolerated. TransCon CNP works by continuously inhibiting the overactive FGFR3 pathway, addressing a rare genetic disorder affecting bone growth and caus...
10-08 20:01
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
An announcement from Ascendis Pharma ( ($ASND) ) is now available. On September...
10-01 04:39
What Does the Market Think About Ascendis Pharma AS?
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which is 4.55% of all regular shares that are available for trading.
09-30 01:00
MBX surges 160% on mid-stage data for hypoparathyroidism drug canvuparatide
MBX Biosciences (NASDAQ:MBX) is up ~160% in Monday morning trading after posting phase 2 data on hypoparathyroidism candidate canvuparatide indicating it met its primary goal. In the 12-week randomize...
09-22 22:20
